Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy TA1126 28 January 2026 28 January 2026 Concizumab for treating ...

Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy TA1126 28 January 2026 28 January 2026 Concizumab for treating ...

A wireless sensor the size of a paperclip could transform care for people living with chronic heart failure, enabling them to monitor their condition daily from home and catch warning signs before ...

Membership details, terms of reference, future meeting dates and past meeting minutes for our 4 technology appraisal committees.

1.2 This recommendation is not intended to affect treatment with apalutamide plus ADT that was started in the NHS before this guidance was published. People having treatment outside this ...

Dupilumab, a simple pre-filled pen that people inject themselves with every two weeks, is the first biologic that targets both the symptoms of COPD and an underlying cause of the disease. It brings ...

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

Suggested remit: To appraise the clinical and cost effectiveness of belantamab mafodotin within its marketing authorisation for treating relapsed or refractory multiple myeloma after 4 or more ...

This guidance has been updated and replaced by NICE technology appraisal guidance 1007 ...

This guidance has been updated and replaced by NICE technology appraisal guidance TA798 ...

This guideline covers recognising, assessing and treating mental health problems in women who are planning to have a baby, are pregnant, or have had a baby or been pregnant in the past year. It covers ...

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.